📷 Image: Wikimedia Commons / Myblessing (owner of informant4u.com)
Business
FSSAI Suspends Biolife Remedies License Over Food Safety Violations
✍️ Business Standard
🗓 08 Oct 2026, 11:37 AM
👁 17
The Food Safety and Standards Authority of India has halted the operating licence of Biolife Remedies after finding the company failed to meet mandatory food safety standards.
New Delhi – The Food Safety and Standards Authority of India (FSSAI) announced the suspension of Biolife Remedies' licence, citing non‑compliance with prescribed food safety regulations. The decision was taken after an inspection revealed several lapses in the company's manufacturing and quality‑control processes.
The authority's report highlighted deficiencies such as inadequate sanitation, failure to maintain temperature controls, and missing documentation for raw material sourcing. These breaches are considered serious under the Food Safety and Standards Act, which mandates strict adherence to hygiene and traceability standards for all food‑related enterprises.
FSSAI officials have given Biolife Remedies a limited window to address the violations and submit a corrective action plan. Until the company demonstrates compliance, its products will remain barred from the market, potentially affecting its supply chain and consumer confidence.
Industry analysts note that the suspension underscores the regulator's heightened scrutiny of nutraceutical and supplement manufacturers, especially those making health claims. The move may prompt other firms to review their own safety protocols to avoid similar penalties.
The authority's report highlighted deficiencies such as inadequate sanitation, failure to maintain temperature controls, and missing documentation for raw material sourcing. These breaches are considered serious under the Food Safety and Standards Act, which mandates strict adherence to hygiene and traceability standards for all food‑related enterprises.
FSSAI officials have given Biolife Remedies a limited window to address the violations and submit a corrective action plan. Until the company demonstrates compliance, its products will remain barred from the market, potentially affecting its supply chain and consumer confidence.
Industry analysts note that the suspension underscores the regulator's heightened scrutiny of nutraceutical and supplement manufacturers, especially those making health claims. The move may prompt other firms to review their own safety protocols to avoid similar penalties.